Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $24.92 down -1.46% from its previous closing price of $25.29. In other words, the price has decreased by -$1.46 from its previous closing price. On the day, 3.06 million shares were traded. ARQT stock price reached its highest trading level at $27.0793 during the session, while it also had its lowest trading level at $24.77.
Ratios:
For a deeper understanding of Arcutis Biotherapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.28 and its Current Ratio is at 3.50. In the meantime, Its Debt-to-Equity ratio is 0.72 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on July 25, 2025, initiated with a Neutral rating and assigned the stock a target price of $18.
On December 30, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $19.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 28 ’25 when Watanabe Todd sold 40,000 shares for $25.03 per share. The transaction valued at 1,001,032 led to the insider holds 806,440 shares of the business.
Todd F watanabe bought 40,000 shares of ARQT for $1,001,033 on Oct 28 ’25. On Oct 02 ’25, another insider, Edwards Larry Todd, who serves as the insider of the company, sold 4,504 shares for $20.04 each. As a result, the insider received 90,263 and left with 178,897 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 3052505344 and an Enterprise Value of 2975211520. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.60 while its Price-to-Book (P/B) ratio in mrq is 18.96. Its current Enterprise Value per Revenue stands at 9.358 whereas that against EBITDA is -89.645.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.99, which has changed by 1.874279 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $25.99, while it has fallen to a 52-week low of $8.21. The 50-Day Moving Average of the stock is 33.02%, while the 200-Day Moving Average is calculated to be 62.23%.
Shares Statistics:
For the past three months, ARQT has traded an average of 2.01M shares per day and 3017190 over the past ten days. A total of 120.29M shares are outstanding, with a floating share count of 107.05M. Insiders hold about 12.61% of the company’s shares, while institutions hold 101.44% stake in the company. Shares short for ARQT as of 1760486400 were 14276026 with a Short Ratio of 7.11, compared to 1757894400 on 16049099. Therefore, it implies a Short% of Shares Outstanding of 14276026 and a Short% of Float of 14.7.
Earnings Estimates
The dynamic stock of Arcutis Biotherapeutics Inc (ARQT) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.01, with high estimates of $0.12 and low estimates of -$0.1.
Analysts are recommending an EPS of between $0.15 and -$0.31 for the fiscal current year, implying an average EPS of -$0.08. EPS for the following year is $0.34, with 5.0 analysts recommending between $0.78 and $0.08.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $109.7M this quarter.It ranges from a high estimate of $112.62M to a low estimate of $107M. As of. The current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $71.36MFor the next quarter, 5 analysts are estimating revenue of $101.66M. There is a high estimate of $102.31M for the next quarter, whereas the lowest estimate is $101M.
A total of 8 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $361.3M, while the lowest revenue estimate was $353.6M, resulting in an average revenue estimate of $357M. In the same quarter a year ago, actual revenue was $196.54MBased on 8 analysts’ estimates, the company’s revenue will be $466.58M in the next fiscal year. The high estimate is $470.1M and the low estimate is $462M.
